Liquidia (LQDA) Other Non-Current Liabilities (2020 - 2026)
Liquidia's (LQDA) quarterly Other Non-Current Liabilities came in at $8.5 million in Q1 2026, up 13.43% year-on-year from $7.5 million in Q1 2025, and up 1.94% quarter-over-quarter from $8.4 million in Q4 2025.
Liquidia (LQDA) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Liquidia's Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $8.5 million for Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 13.43% year-over-year to $8.5 million in Q1 2026; TTM through Mar 2026 was $8.5 million, a 13.43% increase from a year earlier, with the FY2025 full-year figure at $8.4 million, up 14.85% from the prior year.
- Other Non-Current Liabilities grew to $8.5 million in Q1 2026 per LQDA's latest filing, from $8.4 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $8.5 million in Q1 2026 and bottomed at $6.4 million in Q1 2022.
- The 5-year median for Other Non-Current Liabilities is $6.7 million (2024), against an average of $7.2 million.
- Across the five-year window, Other Non-Current Liabilities soared 208.42% in 2022 and advanced 1.5% in 2024, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $6.6 million in 2022, then rose by 1.71% to $6.7 million in 2023, then rose by 8.84% to $7.3 million in 2024, then grew by 14.85% to $8.4 million in 2025, then grew by 1.94% to $8.5 million in 2026.
- Per Business Quant, the three latest LQDA Other Non-Current Liabilities figures stand at $8.5 million (Q1 2026), $8.4 million (Q4 2025), and $8.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.55 Mn |
| Dec 31, 2025 | 8.38 Mn |
| Sep 30, 2025 | 8.28 Mn |
| Jun 30, 2025 | 7.97 Mn |
| Mar 31, 2025 | 7.54 Mn |
| Dec 31, 2024 | 7.30 Mn |
| Sep 30, 2024 | 7.20 Mn |
| Jun 30, 2024 | 6.93 Mn |
| Mar 31, 2024 | 6.71 Mn |
| Dec 31, 2023 | 6.71 Mn |
| Sep 30, 2023 | 6.70 Mn |
| Jun 30, 2023 | 6.70 Mn |
| Mar 31, 2023 | 6.61 Mn |
| Dec 31, 2022 | 6.59 Mn |
| Sep 30, 2022 | 6.56 Mn |
| Jun 30, 2022 | 6.51 Mn |
| Mar 31, 2022 | 6.42 Mn |
| Dec 31, 2021 | 6.14 Mn |
| Sep 30, 2021 | 5.07 Mn |
| Jun 30, 2021 | 3.00 Mn |